Blocking PHGDH overcame dabrafenib resistance in BRAF V600E anaplastic thyroid carcinoma by driving metabolic rewiring, according to findings published in Cell Death Discovery by S.Y. Kim and M.H. You. PHGDH inhibition reduced the resistant state and exposed a metabolic vulnerability tied to aggressive thyroid cancer biology. The study points to a potential combination approach where PHGDH blockade could be paired with BRAF inhibition to prevent or reverse resistance mechanisms. In oncology, identifying a target that functionally addresses a resistance phenotype can accelerate translational strategy if validated in additional models. For pipeline planners, PHGDH is positioned as a candidate for follow-on preclinical work aimed at defining biomarkers of response and narrowing therapeutic windows. The emphasis on metabolic control reinforces a broader development push toward exploiting rewired nutrient pathways in refractory tumors.